Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania

• Published in: BMC infectious diseases Vol. 15; no. 1; p. 368
• Main Authors: Shayo, Grace A, Moshiro, Candida, Aboud, Said, Bakari, Muhammad, Mugusi, Ferdinand M
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 26-08-2015; BioMed Central
• Subjects: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents - administration & dosage; Antitubercular Agents - therapeutic use; Female; Health aspects; Highly active antiretroviral therapy; HIV Infections - complications; HIV Infections - drug therapy; Humans; Isoniazid - administration & dosage; Isoniazid - therapeutic use; Latent Tuberculosis - complications; Latent Tuberculosis - drug therapy; Male; Medical research; Medical screening; Medicine, Experimental; Middle Aged; Patient Compliance; Tanzania; Young Adult; Tanzania
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/s12879-015-1085-7

Proper adherence to isoniazid preventive therapy (IPT) may depend upon the results of tuberculosis (TB) screening test and patients' understanding of their risk of developing active TB. We conducted a study to assess the acceptability, adherence and completion profile of IPT among HIV-infected patients who were clinically screened for latent TB Infection (LTBI).
A multicenter observational study was conducted in Dar es Salaam, Tanzania between February 2012 and March 2014. HIV-infected patients 10 years or older were clinically screened using a validated symptom-based screening tool to rule out active TB. Patients found to have no symptoms in the screening tool were given 300 mg of isoniazid (INH) daily for 6 months. Patients were followed up monthly at the National and Municipal hospital HIV clinics for INH refill and assessment of treatment adherence. Adherence was defined as consumption of 90 % or more of the monthly prescription of INH.
All 1303 invited patients agreed to participate in the study. Of 1303 invited HIV-infected patients, 1283 (98.5 %) were recruited into the study. Twenty eight (2.2 %) did not complete treatment. Those who did not complete the treatment were exclusively adults aged 18 years or older, p = 0.302. The overall mean (±SD) adherence was 98.9 % (±2.9). Adherence level among children aged <18 years (92.2 %) was significantly lower than adherence level among patients aged 18-29 years (98.3 %), 30-49 years (98.8 %) and ≥ 50 years (98.5), p-value = 0.011. Sex, occupation, socio-economic status, duration of HIV infection, being on antiretroviral drugs (ARV) and duration of ARV use were not associated with adherence.
IPT is highly accepted by HIV infected patients. Patients demonstrated high level of adherence to IPT. The level of adherence among children was slightly lower than that among adults. IPT non-completers were exclusively adults. Children might need adult supervision in taking IPT.